Ganesh Benzoplast Limited has informed the Exchange regarding Board meeting held on May 14, 2025.
GANESHBE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganesh Benzoplast's board approved standalone and consolidated audited financial results for Q4 and FY25 (ended March 31, 2025), along with an unmodified auditor opinion from Mittal & Associates. Consolidated PAT excluding exceptional items rose 18% YoY to Rs. 723 million, while PAT after exceptional items fell 38% to Rs. 381 million due to a one-time Rs. 447.31 million charge tied to a legal settlement with Morgan Securities (Rs. 438.63 million) and a GST liability (Rs. 8.68 million). Total revenue declined to Rs. 3,743 million from Rs. 4,771 million, as the LST division deliberately dropped Rs. 700 million of low-margin EPC work. The Chemical division posted strong 243% PBT growth to Rs. 206 million on improved efficiencies. The board also appointed Cost, Internal, and Secretarial auditors for FY26 onward.
Strong underlying earnings growth (18% YoY in core PAT) and a sharp turnaround in the chemical business are positive, but the headline PAT was dragged down by the one-time Morgan settlement charge. The company says the settlement removes earlier operational constraints without hurting liquidity, which could support cleaner earnings going forward. Investors should watch whether the chemical margin gains and higher-margin LST mix sustain in FY26.